Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20200428047228N2
IRCT20200428047228N2
Recruiting
Phase 3

Evaluation of the efficiency of hydroxychloroquine drug regimen in comparison with hydroxychloroquine + azithromycin in hospitalized patients with covid-19 in the intensive care unit

Quality Improvement of Intensive Care Research Center- Shahid Beheshti University0 sites40 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCOVID-19.U07.1 - COVID-19COVID-19

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
COVID-19.
Sponsor
Quality Improvement of Intensive Care Research Center- Shahid Beheshti University
Enrollment
40
Status
Recruiting
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Quality Improvement of Intensive Care Research Center- Shahid Beheshti University

Eligibility Criteria

Inclusion Criteria

  • •Diagnosis of COVID\-19 based on either ground glass appearance in chest CT scan or positive RT\-PCR test for COVID\-19
  • •Requiring hospitalization on the basis of level of consciousness,blood pressure, kidney and liver failure
  • •Patient's age between 16 and 100 years
  • •Signed informed consent form

Exclusion Criteria

  • •Chronic liver and kidney failure
  • •HIV patients
  • •pregnancy and breast feeding
  • •QT interval more than 500 milliseconds

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic HIV-infected patients (HCQ-01) - Hydroxychloroquine studyHIV infectionMedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infection
EUCTR2007-005057-36-GBMedical Research Council
Completed
Not Applicable
HCQ-01 Trial: evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic human immunodeficiency virus (HIV) infected patients
ISRCTN30019040Medical Research Council Clinical Trials Unit (MRC CTU) (UK)90
Not yet recruiting
Phase 3
Efficacy of hydroxychloroquine in graves disease in addition to antithyroid drugs.Health Condition 1: E050- Thyrotoxicosis with diffuse goiter
CTRI/2023/07/054894IPQA laboratories
Recruiting
Not Applicable
Evaluate the efficacy of hydroxychloroquine in the prevention of SARS-COV2 infection in high risk health care workers
IRCT20200414047076N1Esfahan University of Medical Sciences160
Active, not recruiting
Not Applicable
Efficacy of the treatment with hydroxychloroquine in non responders HIV-infected HAART-treated patients - NDHIV infection (immunological nonresponders).MedDRA version: 9.1Level: LLTClassification code 10008922
EUCTR2009-012499-28-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)40